Foravirumab
Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[1] It is under development by Sanofi/Crucell.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | rabies virus glycoprotein |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C6400H9914N1718O1998S44 |
Molar mass | 144304.38 g·mol−1 |
(what is this?) (verify) |
References
- International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
- Khardori NM (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 978-1-4557-1207-6.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.